Apellis Pharmaceuticals, Inc. (APLS) has 20 tenedores institucionales e internos conocidos registrados. El mayor tenedor es Morningside Venture Investments Ltd con 12,806,342 acciones. Otros tenedores destacados incluyen Deschatelets Pascal y Francois Cedric.
En los últimos 12 meses, los internos han realizado 86 transacciones en APLS acciones — 32 compras (valoradas en $19.26M) y 39 ventas (valoradas en $10.82M). Las ventas internas han superado las compras durante este período.
APLS Participación de Insiders
Principal Titular
Morningside Venture Investments Ltd
12,806,342 acciones
Compras (12 meses)
32
$19.26M valor
Ventas (12 meses)
39
$10.82M valor
Actividad de Transacciones (12 meses)
Principales Titulares Internos
| # |
Nombre |
Cargo |
Acciones en Propiedad |
Última Declaración |
Tamaño Relativo |
| 1 |
Morningside Venture Investments Ltd |
10 Percent Owner |
12,806,342 |
2021-11-18 |
|
| 2 |
Deschatelets Pascal |
Chief Scientific Officer |
1,177,222 |
2026-01-30 |
|
| 3 |
Francois Cedric |
Chief Executive Officer |
372,815 |
2026-03-13 |
|
| 4 |
Sullivan Timothy Eugene |
Chief Financial Officer |
152,041 |
2026-01-30 |
|
| 5 |
Watson David O. |
General Counsel |
144,517 |
2026-01-30 |
|
| 6 |
Boucher Kelley |
Chief People Officer |
127,804 |
2026-01-30 |
|
| 7 |
Nicholson Nur |
Chief Technical Officer |
116,338 |
2026-01-30 |
|
| 8 |
Delong Mark Jeffrey |
Chief Business & Strat Officer |
114,591 |
2026-02-13 |
|
| 9 |
Meltzer Leslie |
Chief Research and Development |
107,024 |
2026-01-30 |
|
| 10 |
Grossi Federico |
Chief Medical Officer |
94,884 |
2023-01-09 |
|
| 11 |
Baumal Caroline |
Chief Medical Officer |
86,527 |
2026-01-23 |
|
| 12 |
Townsend Adam J. |
Chief Commercial Officer |
84,050 |
2025-01-30 |
|
| 13 |
Lewis Karen |
Chief People Officer |
70,251 |
2025-01-30 |
|
| 14 |
Chopas James George |
VP/chief Accounting Officer |
65,955 |
2026-01-30 |
|
| 15 |
Eisele Jeffrey |
Chief Development Officer |
55,312 |
2025-01-30 |
|
| 16 |
Scheibler Lukas |
Chief Research Officer |
39,391 |
2023-12-05 |
|
| 17 |
Brown Victoria L. |
Program Team Lead |
23,556 |
2023-01-24 |
|
| 18 |
Chan Gerald |
Director |
14,684 |
2026-01-05 |
|
| 19 |
Dunlop A. Sinclair |
Director |
14,684 |
2026-01-05 |
|
| 20 |
Fonteyne Paul R. |
Director |
14,684 |
2026-01-05 |
|
Transacciones Recientes (últimos 12 meses)
| Fecha |
Nombre |
Cargo |
Tipo |
Acciones |
Precio |
Valor |
| 2026-03-31 |
Biogen Inc. |
Other: See Footnotes |
Desconocido |
- |
- |
- |
| 2026-03-11 |
Francois Cedric |
Chief Executive Officer |
Donación (Recibida) |
64,869 |
- |
- |
| 2026-03-02 |
Dolsten Mikael |
Director |
Desconocido |
- |
- |
- |
| 2026-02-27 |
Dolsten Mikael |
Director |
Concesión de RSU |
14,312 |
- |
- |
| 2026-02-11 |
Delong Mark Jeffrey |
Chief Business & Strat Officer |
Venta Informativa |
368 |
$22.15 |
$8.15K |
| 2026-02-03 |
Francois Cedric |
Chief Executive Officer |
Ejercicio de Opciones (Venta) |
8,840 |
$3.76 |
$33.24K |
| 2026-01-28 |
Meltzer Leslie |
Chief Research and Development |
Concesión de RSU |
45,220 |
- |
- |
| 2026-01-28 |
Boucher Kelley |
Chief People Officer |
Concesión de RSU |
30,146 |
- |
- |
| 2026-01-28 |
Delong Mark Jeffrey |
Chief Business & Strat Officer |
Concesión de RSU |
36,606 |
- |
- |
| 2026-01-28 |
Chopas James George |
VP/chief Accounting Officer |
Concesión de RSU |
16,150 |
- |
- |
| 2026-01-28 |
Nicholson Nur |
Chief Technical Officer |
Concesión de RSU |
45,220 |
- |
- |
| 2026-01-28 |
Sullivan Timothy Eugene |
Chief Financial Officer |
Concesión de RSU |
58,140 |
- |
- |
| 2026-01-28 |
Francois Cedric |
Chief Executive Officer |
Concesión de RSU |
195,952 |
- |
- |
| 2026-01-28 |
Deschatelets Pascal |
Chief Scientific Officer |
Concesión de RSU |
25,840 |
- |
- |
| 2026-01-28 |
Watson David O. |
General Counsel |
Concesión de RSU |
55,986 |
- |
- |
| 2026-01-22 |
Baumal Caroline |
Chief Medical Officer |
Venta Informativa |
2,797 |
$21.77 |
$60.88K |
| 2026-01-22 |
Delong Mark Jeffrey |
Chief Business & Strat Officer |
Venta Informativa |
3,371 |
$21.77 |
$73.37K |
| 2026-01-22 |
Chopas James George |
VP/chief Accounting Officer |
Venta Informativa |
2,064 |
$21.77 |
$44.92K |
| 2026-01-22 |
Nicholson Nur |
Chief Technical Officer |
Venta Informativa |
7,725 |
$21.77 |
$168.14K |
| 2026-01-22 |
Sullivan Timothy Eugene |
Chief Financial Officer |
Venta Informativa |
10,287 |
$21.77 |
$223.9K |
| 2026-01-22 |
Francois Cedric |
Chief Executive Officer |
Venta Informativa |
27,192 |
$21.77 |
$591.84K |
| 2026-01-22 |
Deschatelets Pascal |
Chief Scientific Officer |
Venta Informativa |
5,928 |
$21.77 |
$129.03K |
| 2026-01-22 |
Watson David O. |
General Counsel |
Venta Informativa |
7,832 |
$21.77 |
$170.47K |
| 2026-01-20 |
Baumal Caroline |
Chief Medical Officer |
Venta Informativa |
1,882 |
$19.79 |
$37.25K |
| 2026-01-20 |
Delong Mark Jeffrey |
Chief Business & Strat Officer |
Venta Informativa |
1,334 |
$19.79 |
$26.4K |
